XL177A

Overview

XL177A is a covalent USP7 inhibitor that blocks the deubiquitinase activity of USP7 . XL177A destabilizes non-canonical PRC1 complexes or KDM6A and reduces chromatin deposition of H2AK119Ub , thereby relieving the repression of neuronal differentiation programs. Meanwhile, XL177A also regulates the ELOF1-UVSSA-USP7 -nuclear β-catenin axis, decreasing the transcription levels of related proteins and the accumulation of nuclear β-catenin . XL177A exerts antiviral effects by reducing the expression levels of coronavirus receptors, and exhibits inhibitory activity against APC -mutated colorectal cancer cells, neuroblastoma, and coronaviruses including SARS-CoV-2 variants. XL177A is mainly used in studies related to colorectal cancer , neuroblastoma, and coronavirus infections.

Application

Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Deubiquitinase | Products > Signaling Pathways > Histone Demethylase | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-138794
• CAS No.: 2417089-74-6
• Molecular Formula: C48H57ClN8O5
• Molecular Weight: 861.47
• Purity: 99.60%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 1.25 mg/mL (1.45 mM); Clear solution
• Availability: In-stock

Source

Original product source